姓名：周红刚
职称：教授，博导
职务：5357cc拉斯维加斯院长助理/转化中心主任/仪器平台主任
学科方向：分子药理学
招生方向：分子与细胞生物学，临床免疫与药理学，生物工程与制药学
通讯地址：天津市津南区海河教育园同砚路38号5357cc拉斯维加斯，300350
电话：022-85358566
电子邮件：honggang.zhou@nankai.edu.cn
【个人简介】
博士毕业于英国雷丁大学（University of Reading, UK）5357cc拉斯维加斯药理专业；2011年至今在5357cc拉斯维加斯分别任讲师，副教授（硕导），教授（博导）。主要研究针对器官炎症/纤维化和肿瘤等适应症的新靶点和新机制，以及包括化药、生物药和改良型创新药物研发等。主持“国自然面上基金”2项、青年项目1项、主持“天津市科技重大专项”1项；作为骨干参与“国家重大专项”2项，天津市科技重大专项与工程1项；主持承担企业横向课题15项（纵向和横向课题合计到账金额为1500余万元）。作为主要研究者进行了多个1类新药临床前研究，获批新药临床批件2件（包括我校首个临床批件证书）。共申报发明专利121项，获得授权42项；共发表文章139篇，包括在Science Advances，Molecular Therapy，Signal Transduction and Targeted Therapy杂志上发表SCI文章111篇，h-index为30。担任“Journal of Advanced Research”、“ Bioengineered”、“Biochemical Pharmacology”等33个期刊审稿人。担任“天津市药理学会呼吸与危重症医学专业委员会”第一届委员，“天津市医疗健康学会呼吸疾病专业委员会”委员；“天津市中药传承创新发展专家委员会”委员。
入选了天津市“用三年时间引进千名以上高层次人才”和“滨海新区天津市131创新型第二层次”人才称号。连续四年指导研究生获得国家奖学金和我校一等奖学金，2021年获“我校优秀硕士学位论文指导教师”称号。指导大学生创新创业大赛，共获国家/天津市/校级奖共计30余次，其中获国家铜奖2次，天津市各奖项12次，2020年获“我校创新创业优秀指导教师”称号。
【主要研究方向】
1. 聚焦疾病方向：肺间质病、器官纤维化（皮肤，心脏，肝，肾纤维化）、肿瘤（胃癌靶向治疗）、免疫炎症疾病
2. 疾病创新靶点机制研究及基于临床需求的创新药物研发：小分子化药，抗体药物（单抗、抗体偶联药物），小核酸药物
3. 创新药物的体内外药物代谢与药物动力学研究
4. 药物新剂型在治疗肺部疾病及肿瘤疾病领域的应用
【在研课题】（有硕士名额，欢迎同学们咨询）
一、抗肺纤维化药物研发及特发性肺纤维化致病机制研究
1. 创新化药和生物药（单克隆抗体、抗体偶联药物、多肽和核酸药物）在肺纤维化的作用机制研究与药物开发
2. 针对特发性肺纤维化 1类新药CP0116的机制机理与临床前研究（国家十三五重大新药创制科技重大专项“治疗特发性肺纤维化创新药物的研发”）
3. 特发性肺纤维化潜在创新靶点作用机制研究（国家自然科学基金面上项目）
4. 新冠肺炎临床药物（瑞德西韦、阿兹夫定等）和中药单体对细胞因子风暴和治疗后肺纤维化的作用研究（天津市科技局“新型冠状病毒感染应急防治”科技重大专项）
5. “上市药物再开发”与中药单体治疗肺纤维化作用药效和机制研究
6. 特发性肺纤维化急性加重（AE- IPF）相关药物研发
二、器官纤维化筛选评价体系构建及活性先导化合物成药性评价
1. 器官纤维化筛选评价体系构建及活性先导化合物成药性评价（天津市科技计划项目“肺纤维化药物研发平台建设”）
2. 皮肤纤维化类瘢痕增生疾病药物筛选体系建立及治疗药物研发
3. 心脏纤维化高通量药物筛选体系建立及治疗药物研发
4. 肝脏纤维化和NASH新药开发以及药效及药理作用研究
5. 肾脏纤维化新药开发以及药效及药理作用研究
三、呼吸系统、免疫炎症和代谢相关疾病评价体系构建及活性先导化合物成药性评价
1. 结缔组织疾病相关间质性肺疾病（CTD-ILD）药物筛选体系建立及先导化合物成药性评价
2. 急性肺损伤筛选评价体系构建及活性先导化合物成药性评价
3. 免疫炎症疾病高通量细胞筛选评价体系构建及活性先导化合物成药性评价
4. 消化系统疾病动物模型（炎性肠病IBD为主）药物开发以及机制机理研究
5. 银屑病动物模型建立及优势化合物筛选
6. 脓毒症动物模型建立及优势化合物筛选
7. 术后复发白内障动物模型建立及优势化合物筛选
四、靶向抗肿瘤药物开发及抗肿瘤药理机制研究
1. 肺癌合并肺纤维化动物模型建模方法研究及药物筛选与药效评价
2. 治疗胃癌的靶向FGFR创新小分子化药研发
3.PAR1介导的口腔癌铁死亡的分子机制研究
4. 靶向STAT3的抗肿瘤药物筛选及药理机制研究
5. PAR1-STAT3转录复合体在肿瘤恶性演进中的分子机制研究
6. 天然产物抗肿瘤活性及作用机制研究
【近期论文发表情况】
1. Hailong Li, Jinhe Li, Yayue Hu, Ruotong Zhang, Xiaoting Gu, Yiying Wei, Shanshan Zhang, Xuefen Chen, Luqing Wei, Xiaohe Li, Songtao Gu, Jin Jin, Hui Huang*, Honggang Zhou*, Cheng Yang*. FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit idiopathic pulmonary fibrosis. International Journal of Biological Sciences, 2023.
2. Ting Xiao, Dandi Gao, Xiaoting Gu, Yanping Zhang, Yuxin Zhu, Zihui Zhang, Yiming He, Luqing Wec, Hongli Li*, Honggang Zhou*, Cheng Yang*. Flavokawain Aameliorates pulmonary fibrosis by inhibiting the TGF-β signaling pathway and CXCL12/CXCR4 axis. European Journal of Pharmacology, 2023.
3. Ting Xiao, Jiali Bao, Jiao Tian, Rong Lin, Zihui Zhang, Yuxin Zhu, Yiming He, Dandi Gao, Ronghao Sun, Fubo Zhang, Yexin Cheng, Jiadelati Shaletanati, Honggang Zhou*, Chunfeng Xie*, Cheng Yang*. Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT. Phytomedicine, 2023
4. Xiaohe Li, Xiaoyang Ma, Yang Miao, Jianwei Zhang, Buri Xi, Wenqi Li, Qianyi Zhang, Li Chen, Yue Yang, Hongli Li, Luqing Wei,* Honggang Zhou,* Cheng Yang*. Duvelisib Attenuates Bleomycin-Induced Pulmonary Fibrosis via Inhibiting the PI3K/Akt/mTOR Signaling Pathway. Journal of Cellular and Molecular Medicine, 2023.
5. Hailong Li, Ruotong Zhang, Yayue Hu, Jinhe Li, Ying Yang, Dan Wu, Xiaoting Gu, Fubo Zhang*, Honggang Zhou*, Cheng Yang*. Axitinib attenuates the progression of liver fibrosis by restoring mitochondrial function. International Immunopharmacology, 2023.
6. Ting Xiao, Shanfa Ren, Jiali Bao, Dandi Gao, Ronghao Sun, Xiaoting Gu, Jingjing Gao, Shanshan Chen, Jin Jin, Luqing Wei, Chunwa Wu, Cheng Yang*, Guang Yang*, Honggang Zhoua*. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study. European Journal of Pharmacology, 2023.
7. Yang Miao, Yanhua Wang, Zhun Bi, Kai Huang, Jingjing Gao, Xiaohe Li, Shimeng Li1, Luqing Wei*, Honggang Zhou* and Cheng Yang*. Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice. BMC Pulmonary Medicine, 2023.
8. Shaoyan Gao, Xiaohe Li, Qiuyan Jiang, Qing Liang, Fangxia Zhang, Shuangling Li, Ruiqin Zhang, Jiaoyan Luan, Jingyan Zhu, Xiaoting Gu, Ting Xiao, Hui Huang, Shanshan Chen, Wen Ning*, Guang Yang*, Cheng Yang*, Honggang Zhou*. PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling. Science Advances, 2022.
9. Shanshan Chen,§ Yuli Wei,§ Shimeng Li,§ Yang Miao,§ Jinying Gu, Yunyao Cui, Zhichao Liu, Jingjing Liang, Luqing Wei, Xiaohe Li,* Honggang Zhou,* Cheng Yang, *. Zanubrutinib Attenuates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway. International Immunopharmacology, 2022.
10. Yang Miao, Xiaohe Li, Yue Yang, Jianwei Zhang, Li Chen, Qianyi Zhang, Wenqi Li, Ying Liu, Xianfeng Zhang,*, Ruimin Gu,*, Cheng Yang*. Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway. International Immunopharmacology, 2022.
11. Bowen Liu, Qiuyan Jiang, Ruxuan Chen, Shaoyan Gao, Qin Xia, Jingyan Zhu, Fangxia Zhang, Chi Shao, Xiangning Liu, Xiaohe Li, Honggang Zhou, * Cheng Yang, * Hui Huang*. Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling. International Immunopharmacology, 2022.
12. Hailong Li, Jinhe Li, Ting Xiao, Yayue Hu, Ying Yang, Xiaoting Gu, Ge Jin, Hailong Cao*, Honggang Zhou* and Cheng Yang. Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways. Frontiers in Pharmacology, 2022.
13. Kun Zhang, Jingjing Liang, Ning Wang, Ning Li, Yurui Jiang, Xiaohe Li*, Cheng Yang*, Honggang Zhou*, Guang Yang*. Discovery of a novel Pleuromutilin derivative as anti-IPF lead compound via high-throughput assay. European Journal of Medicinal Chemistry, 2022.
14. Xiaohe Li, Yuli Wei, Shimeng Li, Jingjing Liang, Zhichao Liu, Yunyao Cui, Jingjing Gao, Zhongyi Yang, Lei Li, Honggang Zhou*, Shanshan Chen*, Cheng Yang*. Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization. International Immunopharmacology, 2022.
15. Hai-long Li, Yi-ying Wei, Xiao-he Li, Shan-shan Zhang, Ruo-tong Zhang, Jin-he Li, Bo-wei Ma, Shuai-bo Shao, Zi-wei Lv, Hao Ruan, Honggang Zhou* and Cheng Yang. Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis. Acta Pharmacologica Sinica，2022.
16. Ting Xiao, Shanfa Ren, Jiali Bao, Dandi Gao, Ronghao Sun, Xiaoting Gu, Jingjing Gao, Shanshan Chen, Jin Jin, Luqing Wei, Chunwa Wu, Cheng Yang*, Guang Yang*, Honggang Zhou*. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STA1/3 signaling pathway-an experimental in vitro and vivo study. European Journal of Pharmacology, 2022
17. Ming Wang, Shanfa Ren, Zhun Bi, Liang Zhang, Mengqi Cui, Ronghao Sun, Jiali Bao, Dandi Gao, Bo Yang, Xiaoping Li, Mingjiang Li, Ting Xiao*, Honggang Zhou*, Cheng Yang. Myricetin reverses epithelial–endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1. Phytotherapy Research, 2022.
18. Ting Xiao, Mengqi Cui, Caijuan Zheng, Peipei Zhang, Shanfa Ren, Jiali Bao, Dandi Gao, Ronghao Sun, Ming Wang, Jianping Lin, Liang Zhang, Mingjiang Li, Dongmei Li*, Honggang Zhou* and Cheng Yang*. Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS‐CoV‐2 Replication by Targeting Mpro and Sepsis in Mice, Inflammation, 2022.
19. Xiaohe Li, Qing Liang, Shaoyan Gao, Qiuyan Jiang, Fangxia Zhang, Ruiqin Zhang, Hao Ruan, Shuangling Li, Jiaoyan Luan, Ruxia Deng, Honggang Zhou*, Hui Huang*, Cheng Yang*. Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. International Immunopharmacology，2022.
20. Ruotong Zhang, Yiying Wei, Shanshan Zhang, Hailong Li, Jinhe Li, Bowei Ma, Xiaoqing Zhu, Xudong Song*, Honggang Zhou*. Inhibitory effect of Idelalisib on selenite-induced cataract in Sprague Dawley rat pups. Current Eye Research，2022.
21. Bo Yang, Ling Ma, Yuli Wei, Yunyao Cui, Xiaohe Li, Yiying Wei, Shanshan Zhang, Liang Zhang, Honggang Zhou*, Guangshun Wang*, Xiaoping Li*. Isorhamnetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting mTOR signaling pathway. Immunopharmacol Immunotoxicol, 2022.
22. Bo Yang, Rong Wang, Lin-Lin Ji, Xiao-Ping Li, Xiao-He Li, Hong-Gang Zhou, Zhan-Kun He, Hong-Liang Xu, Fan-Jie Meng, Guang-Shun Wang*. Exploration of the Function of Ginsenoside RD Attenuates Lipopolysaccharide-Induced Lung Injury: A Study of Network Pharmacology and Experimental Validation. Shock, 2022.
23. Xiaohe Li, Yinshan Fang, Dingyuan Jiang, Yingying Dong, Yingying Liu, Si Zhang, Jiasen Guo, Chao Qi, Chenjing Zhao, Fangxin Jiang, Yueyue Jin, Jing Geng, Cheng Yang, Hongkai Zhang, Bin Wei, Jiurong Liang, Chen Wang, Huaping Dai, Honggang Zhou*, Dianhua Jiang*, and Wen Ning*. Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases. Molecular Therapy, 2021.
24. Xiaohe Li†, Ling Ma†, Kai Huang†, Yuli Wei, Shida Long, Qinyi Liu, Deqiang Zhang, Shuyang Wu, Wenrui Wang, Guang Yang*, Honggang Zhou* and Cheng Yang*. Regorafenib-Attenuated Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway. International Journal of Molecular Sciences, 2021.
25. Xiaohe Li†, Yanhua Wang†, Jingjing Liang†, Zhun Bi†, Hao Ruan†, Yunyao Cui, Ling Ma, Yuli Wei, Bingchen Zhou, Liang Zhang, Honggang Zhou*, Cheng Yang*. Bergenin attenuates bleomycin-induced pulmonary fibrosis in mice via inhibiting TGF-β1 signaling pathway. Phytotherapy Research, 2021.
26. Xiaohe Li†, Rui Liu†, Yunyao Cui†, Jingjing Liang†, Zhun Bi†, Shimeng Li, Yang Miao, Liang Zhang, Xiaoping Li, Honggang Zhou* and Cheng Yang. Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice. Frontiers in Pharmacology, 2021.
27. Xiaohe Li†, Kai Huang†, Xiaowei Liu†, Hao Ruan†, Ling Ma, Jingjing Liang, Yunyao Cui, Yanhua Wang, Shuyang Wu, Hailong Li, Yuli Wei, Zeping Li, Jingjing Gao, Bo Yang, Xiaoping Li, Guang Yang*, Honggang Zhou* and Cheng Yang*. Ellagic Acid Attenuates BLM-Induced Pulmonary Fibrosis via Inhibiting Wnt Signaling Pathway. Frontiers in Pharmacology, 2021.
28. Hailong Li, Rui Liu, Ruotong Zhang, Shanshan Zhang, Yiying Wei, Liang Zhang, Honggang Zhou* and Cheng Yang*. Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice. Frontiers in Pharmacology, 2021.
29. Ting Xiao, Mengqi Cui, Caijuan Zheng, Ming Wang, Ronghao Sun, Dandi Gao, Jiali Bao, Shanfa Ren, Bo Yang, Jianping Lin, Xiaoping Li, Dongmei Li*, Cheng Yang* and Honggang Zhou*. Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation. Frontiers in Pharmacology，2021.
30. Xiaohe Li, § Xiaowei Liu, § Ruxia Deng, § Shaoyan Gao, § Qiuyan Jiang, Rui Liu, Hailong Li, Yang Miao, Yunqian Zhai, Shanshan Zhang, Zhenzhen Wang, Yimeng Ren, Wen Ning, Honggang Zhou*, Cheng Yang*. Betulinic acid Attenuated Bleomycin-induced Pulmonary Fibrosis by Effectively Intervening Wnt/β-catenin Signaling. Phytomedicine, 2021.
31. Xiaohe Li, Ling Ma, Yuli Wei, Jinying Gu, Jingjing Liang, Shimeng Li, Yunyao Cui, Rui Liu, Hui Huang, Cheng Yang, Honggang Zhou*. Cabozantinib ameliorates lipopolysaccharide-induced lung inflammation and bleomycin--induced early pulmonary fibrosis in mice. International Immunopharmacology，2021.
32. Shuangling Li, Shaoyan Gao, Qiuyan Jiang, Qing Liang, Jiaoyan Luan, Ruiqin Zhang, Fangxia Zhang, Hao Ruan, Xiaohe Li, Xiaoping Li, Honggang Zhou*, Cheng Yang. Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization. International Immunopharmacology，2021.
33. Xiaohe Li, Hailong Li, Shanshan Zhang, Ruotong Zhang, Jinhe Li, Yiying Wei, Cheng Yang, Fubo Zhang*, Honggang Zhou*. Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P/phosphatidylinositol-3-hydr oxykinase signalling pathway. Journal of Cellular and Molecular Medicine，2021.
34. Xiaohe Li†, Yunqian Zhai†, Buri Xi†, Wei Ma†, Jianwei Zhang, Xiaoyang Ma, Yang Miao, Yongjian Zhao, Wen Ning,*, Honggang Zhou,* and Cheng Yang. Pinocembrin Ameliorates Skin Fibrosis via Inhibiting TGF‐β1 Signaling Pathway. Biomolecules，2021.
35. Heng Zhang, Zhi Chang, Lu-ning Qin, Bin Liang, Jing-xia Han, Kai-liang Qiao, Cheng Yang, Yan-rong Liu*, Honggang Zhou* and Tao Sun*. MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells, Signal Transduction and Targeted Therapy, 2021.
36. Ting Xiao, Yuli Wei, Mengqi Cui, Xiaohe Li, Hao Ruan, Liang Zhang, Jiali Bao, Shanfa Ren, Dandi Gao, Ming Wang, Ronghao Sun, Mingjiang Li, Dongmei Li*, Cheng Yang*, Honggang Zhou*. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis, Phytomedicine, 2021.
37. Wenhua Gan, § Xiaohe Li, § Yunyao Cui, § Ting Xiao, Rui Liu, Ming Wang, Yiying Wei, Mengqi Cui, Shanfa Ren, Kaiyue Helian, Wen Ning, Honggang Zhou*, Cheng Yang*. Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-κB-NLRP3 inflammasome signaling pathway. International Immunopharmacology, 2021.
38. Xiaohe Li, Buri Xi, Yang Miao, Xiaoyang Ma, Jianwei Zhang, Jingjing Gao, Wenguo Wei*, Honggang Zhou*, Cheng Yang. Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling. International Immunopharmacology，2021.
39. Hao Ruan†, Jiaoyan Luan†, Shaoyan Gao†, Shuangling Li, Qiuyan Jiang, Rui Liu, Qing Liang, Ruiqin Zhang, Fangxia Zhang, Xiaohe Li, Honggang Zhou* and Cheng Yang. Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway. Molecules，2021.
40. Hao Ruan, Shaoyan Gao, Shuangling Li, Jiaoyan Luan, Qiuyan Jiang, Xiaohe Li, Huijun Yin*, Honggang Zhou* and Cheng Yang*. Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway. Molecules，2021.
41. Mingjiang Li, Bo Yang, Xiaoping Li, Haixia Ren, Liang Zhang, Lei Li, Wei Li, Xuhui Wang, Honggang Zhou, Weidong Zhang. Identification of Prognostic Factors Related to Super Enhancer-Regulated ceRNA Network in Metastatic Lung Adenocarcinoma. International Journal of General Medicine, 2021.
42. Bo Yang #, Lin-Lin Ji #, Hong-Liang Xu #, Xiao-Ping Li, Hong-Gang Zhou, Ting Xiao, Xiao-He Li, Zhou-Yong Gao, Jian-Zhong Li, Wei-Dong Zhang, Guang-Shun Wang, Ming-Jiang Li. Zc3h12d, a Novel of Hypomethylated and Immune-Related for Prognostic Marker of Lung Adenocarcinoma. Journal of Inflammation Research, 2021.
43. 陈莉，朱婧妍，高劭妍，谷小婷，李霄鹤*，周红刚*. 尼达尼布治疗间质性肺疾病的作用机制研究进展. 中国药理学通报，2023.
44. 陈莉，朱雨昕，李霄鹤，肖婷，谷小婷*，周红刚*. 瘢痕疙瘩细胞和分子机制研究进展. 中国药理学通报，2023.
45. 肖婷，暴嘉丽，刘湘宁，黄慧*，周红刚*. 特发性肺纤维化合并非小细胞肺癌的致病机制及潜在治疗药物研究进展. 中国肺癌杂志，2022.
46. 卫怡颖，马博威，李海龙，宋旭东*，周红刚*. 中药单体治疗白内障的研究进展. 中国老年学杂志，2022.
47. 李海龙，张若彤，卫怡颖，张杉杉，马博威，李霄鹤*，周红刚*. 环状 RNA 在肺纤维化中的作用研究进展. 中国药理学与毒理学杂志，2022.
48. 张杉杉，李海龙，李晓平，李霄鹤*，周红刚*. 酪氨酸激酶抑制剂与器官纤维化研究进展. 中国药学杂志，2022.
49. 崔梦奇，任善发，王 明，高丹迪，肖 婷*，周红刚*，杨 诚*. PARs在IPF中的作用及其靶向药物研究进展. 生命科学，2021.
50. 姜秋燕，梁 庆，高劭妍，李霄鹤，黄 慧，周红刚*. 特发性肺纤维化治疗药物研究进展. 中国新药杂志，2021.
51. 邓如霞，张瑞芹，高劭妍，黄慧，李霄鹤，周红刚*. 尼达尼布抗器官纤维化研究进展. 中国药学杂志，2021.
52. 苗洋，李霄鹤，翟芸芊，白佳坤，马晓阳，希布日，张建伟，周红刚*，杨诚*. 特发性肺纤维化抗体药物研发进展. 药学学报，2021.
53. 卫怡颖，李诗檬，魏文国，周红刚*. 银屑病治疗药物的研究进展. 中国当代医药，2021.